3 results
Primary:• To prove the superiority of a 12-week add-on treatment with 3.2 g/daygastro-resistant phosphatidylcholine granules (LT-02) in at least one of twodifferent dosing regimens versus LT-02 placebo for the induction ofremission in patients with…
Primairy Objective* To test whether 5-ASA reduces the occurrence of colonic benign or malignant neoplasia compared to placebo in Lynch syndrome (LS) patients as detected by any colonoscopy until the end of study.Secondary Objectives* To test wheter…
Part A: To acquire an optimal pharmacokinetic model of [68Ga]Ga-FAPI-46 by which simplified methods to quantify [68Ga]Ga-FAPI-46 PET signal will be validated. Part B: To determine the test-retest repeatability of the quantitative measurements (as…